The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.

The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.
复制标题

DOI:
10.1016/j.yjmcc.2010.10.021
复制
发表时间:
2011-10
影响因子:
5
通讯作者:
Wang Y
Wang Y
中科院分区:
医学2区
文献类型:
--
作者:
Marber MS;Rose B;Wang Y

文献摘要

参考文献

被引文献

相似文献

p38丝裂原活化蛋白激酶(p38 s)是应激活化的丝氨酸/苏氨酸激酶。它们的激活与心脏中的各种病理应激源有关。激活的p38与广泛的心脏病理学有关,包括肥大、心肌梗死以及收缩性和舒张性心力衰竭。本文综述了p38激酶的不同亚型在心脏疾病中的作用以及TAB-1介导的非经典激活途径,为抑制p38活性治疗心肌肥厚、缺血性损伤和心力衰竭提供理论依据。最后,总结了目前针对p38激酶在心血管疾病中的临床试验,以突出这种治疗方法的潜在前景以及现有的挑战。
The p38 mitogen-activated protein kinases (p38s) are stress activated ser/thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1 mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach.
DOI: 10.1126/science.1067289
发表时间: 2002-02-15
期刊: SCIENCE
影响因子: 56.9
作者:
Ge, BX;Gram, H;Han, JH
通讯作者: Han, JH
DOI: 10.1074/jbc.m210918200
发表时间: 2003-01-24
影响因子: 4.8
作者:
Ge, BX;Xiong, XS;Han, JH
通讯作者: Han, JH
DOI: 10.1074/jbc.274.18.12626
发表时间: 1999-04-30
影响因子: 4.8
作者:
Hasegawa, M;Cuenda, A;Goedert, M
通讯作者: Goedert, M
DOI: 10.1101/gad.1107303
发表时间: 2003-08-15
影响因子: 10.5
作者:
Brancho, D;Tanaka, N;Davis, RJ
通讯作者: Davis, RJ
DOI: 10.1016/j.ceb.2009.01.015
发表时间: 2009-04-01
影响因子: 7.5
作者:
Cohen, Philip
通讯作者: Cohen, Philip